Abstract 184P
Background
Somatic cell reprogramming results in generation of induced pluripotent stem cells (iPSCs) which demonstrate similar gene expression, morphology, epigenetic profile and three-germ layer differentiation capacity to those of embryonic stem cells. Therefore patient-derived iPSCs can act as a powerful tool both for understanding disease mechanism and for regenerative medicine. Cancer cell reprogramming offers a unique model to study tumor initiation and progression as well as to create patient-specific cancer models for toxicity screening and developing personalised therapeutic strategies. Here, we primarily focused on reprogramming grade 4 bladder cancer cell lines to identify potential biomarkers for early cancer detection and cancer immunotherapy.
Methods
Grade 4 bladder cancer cells were transduced with a non-genome integrating Sendai virus system carrying Yamanaka factors Oct3/4, Sox2, Klf4, and c-Myc. Reprogrammed bladder cancer cells were cultured in a feeder-free iPSC system. Pluripotency-associated features were characterised using functional assays, immunofluorescence and western blotting. The nano HPLC LC-MS/MS system was utilised for comprehensive proteome analysis, followed by protein-protein interaction network analysis via STRING.
Results
Reprogrammed bladder cancer cells expressed pluripotency-associated factors, changed cell morphology and motility. Proteomic analysis showed a decrease in the proteins related to the immune system process. Protein-protein interaction network analysis highlighted key proteins involved in antigen processing and presentation of endogeneous peptide antigen via MHC class I and interleukin-27-mediated signaling pathway.
Conclusions
After somatic cell reprogramming, ancestral cancer cells shift from malignancy to benignity in their proteome, affecting various cellular processes including immune system function, stem cell maintenance, differentiation, apoptosis, cell adhesion, and motility. Major changes were observed in the proteins of the immune system, indicating that the unique immunogenicity of cancer cell-derived iPS cells could be used in targeted therapies and potential drug design.
Legal entity responsible for the study
Banu Iskender Izgi.
Funding
Health Institutes of Türkiye (TUSEB).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
7P - ACOX2 disturbs the stability of MRE11-RAD50-NBS1 complex and shapes activated immune tumor microenvironment in clear cell renal cell carcinoma
Presenter: Shiqi Ye
Session: Poster Display session
Resources:
Abstract
9P - CXCR6+PD-1- Tissue Resident memory T cells are associated with poor prognosis in patients with metastatic colorectal cancer
Presenter: Emilien Laloy
Session: Poster Display session
Resources:
Abstract
10P - Tumor-infiltrating lymphocytes and tertiary lymphoid structures in oral cavity squamous cell carcinoma in non-smokers and non-drinkers: Predict clinical outcome
Presenter: Israa Laklouk
Session: Poster Display session
Resources:
Abstract
11P - Tumor-infiltrating lymphocytes on routine H&E staining with automated quantification predict outcomes in resectable non-small cell lung cancer
Presenter: Guus Heuvel
Session: Poster Display session
Resources:
Abstract
12P - Epithelial-mesenchymal transition facilitates response to AXL/PD-1 inhibition in relapsed mesothelioma
Presenter: Essa Baitei
Session: Poster Display session
Resources:
Abstract
14P - Integrated genomic analysis of whole genomes to derive a biomarker of durable response to immunotherapy in melanoma
Presenter: Irene Lobon
Session: Poster Display session
Resources:
Abstract
15P - Verteporfin might potentiate the effects of anti-PD-1 therapy in melanoma-bearing mice model
Presenter: Szonja Kovács
Session: Poster Display session
Resources:
Abstract
16P - Immune checkpoint blockade and HLA-related epistasis in melanoma: Genetic determinants of response and toxicity
Presenter: Martin Little
Session: Poster Display session
Resources:
Abstract
17P - Identification PD-L1-associated lncRNA biomarkers for immunoregulation in ovarian cancer
Presenter: Hee Jung Kim
Session: Poster Display session
Resources:
Abstract
19P - Genetic profiling of early triple-negative breast cancer patients with an indication for neoadjuvant pembrolizumab
Presenter: Bogdan Popescu
Session: Poster Display session
Resources:
Abstract